<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="apt70183" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Aliment Pharmacol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Aliment Pharmacol Ther</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">APT</journal-id><journal-title-group><journal-title>Alimentary Pharmacology &amp; Therapeutics</journal-title></journal-title-group><issn pub-type="ppub">0269-2813</issn><issn pub-type="epub">1365-2036</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12203144</article-id><article-id pub-id-type="pmcid-ver">PMC12203144.1</article-id><article-id pub-id-type="pmcaid">12203144</article-id><article-id pub-id-type="pmcaiid">12203144</article-id><article-id pub-id-type="pmid">40448303</article-id><article-id pub-id-type="doi">10.1111/apt.70183</article-id><article-id pub-id-type="publisher-id">APT70183</article-id><article-id pub-id-type="other">APT-1931-2024.R2</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Underdiagnosis of Alpha&#8208;1 Antitrypsin Deficiency</subject></subj-group></article-categories><title-group><article-title>Underdiagnosis of Alpha&#8208;1 Antitrypsin Deficiency in Cirrhotic Liver Transplant Candidates: Findings From a Multicenter Retrospective Study</article-title></title-group><contrib-group><contrib id="apt70183-cr-0001" contrib-type="author"><name name-style="western"><surname>Evain</surname><given-names initials="M">Manon</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9409-2887</contrib-id><xref rid="apt70183-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="apt70183-cr-0002" contrib-type="author"><name name-style="western"><surname>Ruiz</surname><given-names initials="I">Isaac</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3711-1287</contrib-id><xref rid="apt70183-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="apt70183-cr-0003" contrib-type="author"><name name-style="western"><surname>Antonini</surname><given-names initials="T">Teresa</given-names></name><xref rid="apt70183-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="apt70183-cr-0004" contrib-type="author"><name name-style="western"><surname>Lassailly</surname><given-names initials="G">Guillaume</given-names></name><xref rid="apt70183-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="apt70183-cr-0005" contrib-type="author"><name name-style="western"><surname>Mazzola</surname><given-names initials="A">Alessandra</given-names></name><xref rid="apt70183-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="apt70183-cr-0006" contrib-type="author"><name name-style="western"><surname>Debry</surname><given-names initials="PH">Pauline Houssel</given-names></name><xref rid="apt70183-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="apt70183-cr-0007" contrib-type="author"><name name-style="western"><surname>Elkrief</surname><given-names initials="L">Laure</given-names></name><xref rid="apt70183-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="apt70183-cr-0008" contrib-type="author"><name name-style="western"><surname>Anty</surname><given-names initials="R">Rodolphe</given-names></name><xref rid="apt70183-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="apt70183-cr-0009" contrib-type="author"><name name-style="western"><surname>Sebagh</surname><given-names initials="M">Myl&#232;ne</given-names></name><xref rid="apt70183-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="apt70183-cr-0010" contrib-type="author"><name name-style="western"><surname>Ichai</surname><given-names initials="P">Philippe</given-names></name><xref rid="apt70183-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="apt70183-cr-0011" contrib-type="author"><name name-style="western"><surname>Cherqui</surname><given-names initials="D">Daniel</given-names></name><xref rid="apt70183-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="apt70183-cr-0012" contrib-type="author"><name name-style="western"><surname>Samuel</surname><given-names initials="D">Didier</given-names></name><xref rid="apt70183-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="apt70183-cr-0013" contrib-type="author"><name name-style="western"><surname>Kounis</surname><given-names initials="I">Ilias</given-names></name><xref rid="apt70183-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="apt70183-cr-0014" contrib-type="author" corresp="yes"><name name-style="western"><surname>Coilly</surname><given-names initials="A">Audrey</given-names></name><xref rid="apt70183-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>audrey.coilly@universite-paris-saclay.fr</email></address></contrib><contrib id="apt70183-cr-0015" contrib-type="author"><collab collab-type="authors">the GREF 2 group</collab></contrib></contrib-group><aff id="apt70183-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>AP&#8208;HP H&#244;pital Paul Brousse, Centre H&#233;pato&#8208;Biliaire, Paris&#8208;Saclay University</institution>
<city>Villejuif</city>
<country country="FR">France</country>
</aff><aff id="apt70183-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Department of Hepatology and Liver Transplantation, Centre Hospitalier de l'Universite of Montr&#233;al</institution>
<city>Montreal</city>
<country country="CA">Canada</country>
</aff><aff id="apt70183-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">The Lyon liver institute, Everest IHU</named-content>
<named-content content-type="organisation-division">Hepatology Department, Croix Rousse Hospital, Hospices Civils of Lyon, Lyon, France</named-content>
<city>Lyon</city>
<country country="FR">France</country>
</aff><aff id="apt70183-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Service des Maladies de l'Appareil Digestif, Centre Hospitalier Universitaire de Lille (CHU de Lille), Lille, France; European Genomic Institute for Diabetes (EGID), UMR 1190 Translational Research for Diabetes, Inserm, CHU Lille, University of Lille</institution>
<city>Lille</city>
<country country="FR">France</country>
</aff><aff id="apt70183-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>Service d'h&#233;pato&#8208;gastroent&#233;rologie, H&#244;pital La Piti&#233; Salp&#234;tri&#232;re</institution>
<city>Paris</city>
<country country="FR">France</country>
</aff><aff id="apt70183-aff-0006">
<label>
<sup>6</sup>
</label>
<institution>Service des maladies du foie</institution>
<city>CHU Rennes</city>
<country country="FR">France</country>
</aff><aff id="apt70183-aff-0007">
<label>
<sup>7</sup>
</label>
<institution>Facult&#233; de m&#233;decine de Tours et CHRU de Tours, service d'h&#233;pato&#8208;gastroent&#233;rologie, centre de r&#233;f&#233;rence constitutif Maladies Vasculaires du foie, Filfoie, ERN Rare Liver</institution>
<city>Tours</city>
<country country="FR">France</country>
</aff><aff id="apt70183-aff-0008">
<label>
<sup>8</sup>
</label>
<institution>Archet 2 University hospital, Inserm U1065 team 8, universit&#233; C&#244;te d&#8217;Azur</institution>
<city>Nice</city>
<country country="FR">France</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Audrey Coilly (<email>audrey.coilly@universite-paris-saclay.fr</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2025</year></pub-date><volume>62</volume><issue seq="90">2</issue><issue-id pub-id-type="pmc-issue-id">491639</issue-id><issue-id pub-id-type="doi">10.1111/apt.v62.2</issue-id><fpage>193</fpage><lpage>203</lpage><history><date date-type="rev-recd"><day>22</day><month>11</month><year>2024</year></date><date date-type="received"><day>16</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>28</day><month>4</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-28 00:25:18.720"><day>28</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alimentary Pharmacology &amp; Therapeutics</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="APT-62-193.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:APT-62-193.pdf"/><abstract><title>ABSTRACT</title><sec id="apt70183-sec-0001"><title>Background and Aims</title><p>Alpha&#8208;1 antitrypsin deficiency (AATD) is a prevalent genetic disorder in Europe causing hepatic fibrosis and often remains undiagnosed, even in severe cases requiring liver transplantation (LT). This study aimed to determine the frequency of pre&#8208;LT diagnosis amongst LT candidates with AATD and to describe their clinical characteristics. A secondary goal was to assess awareness and practices concerning AATD amongst LT specialists in France.</p></sec><sec id="apt70183-sec-0002"><title>Methods</title><p>This retrospective multicenter cohort study included LT candidates diagnosed with AATD based on PAS&#8208;positive staining of explanted livers (1995&#8211;2020) from nine centres in France and Canada. A 22&#8208;question survey was sent to LT specialists in France to assess AATD knowledge and practices.</p></sec><sec id="apt70183-sec-0003"><title>Results</title><p>Amongst 58 patients diagnosed with AATD between 1996 and 2020, 40% were diagnosed pre&#8208;LT, 15% post&#8208;LT and 45% never confirmed. Less than 25% had non&#8208;specific pulmonary symptoms. The survey revealed poor awareness of AATD; 78% of specialists rated their knowledge as very low to moderate. Consistent pre&#8208;LT screening occurred in 59.3% of cases, and 52.5% recommended familial screening upon a confirmed diagnosis.</p></sec><sec id="apt70183-sec-0004"><title>Conclusion</title><p>AATD remains underdiagnosed in pre&#8208;LT assessments and is poorly understood amongst practitioners in France. Improved screening can enhance patient management, especially with emerging potentially curative treatments.</p></sec></abstract><abstract abstract-type="graphical"><p>Only 40% of AATD patients were diagnosed pre&#8208;LT, revealing major gaps in current screening practices. Improved diagnostic practices and new treatments will substantially enhance patient outcomes and overall management of AATD.<boxed-text position="anchor" content-type="graphic" id="apt70183-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="APT-62-193-g001.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="apt70183-kwd-0001">alpha&#8208;1 antitrypsin</kwd><kwd id="apt70183-kwd-0002">genetic</kwd><kwd id="apt70183-kwd-0003">liver transplantation</kwd><kwd id="apt70183-kwd-0004">survey</kwd></kwd-group><counts><fig-count count="1"/><table-count count="4"/><page-count count="11"/><word-count count="6400"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>July 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.7 mode:remove_FC converted:27.06.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="apt70183-ntgp-0001"><fn fn-type="handlingEditor" id="apt70183-note-0001"><p>
<bold>Handling Editor:</bold> Palak J Trivedi</p></fn><fn fn-type="funding" id="apt70183-note-0002"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn></fn-group></notes></front><body id="apt70183-body-0001"><def-list list-content="abbreviations" id="apt70183-dl-0001"><title>Abbreviations</title><def-item><term id="apt70183-li-0001">AAT</term><def id="apt70183-li-0002"><p>alpha1&#8208;antitrypsin</p></def></def-item><def-item><term id="apt70183-li-0003">AATD</term><def id="apt70183-li-0004"><p>alpha1&#8208;antitrypsin deficiency</p></def></def-item><def-item><term id="apt70183-li-0005">ACLF</term><def id="apt70183-li-0006"><p>acute on chronic liver failure</p></def></def-item><def-item><term id="apt70183-li-0007">ALD</term><def id="apt70183-li-0008"><p>alcohol&#8208;related liver disease</p></def></def-item><def-item><term id="apt70183-li-0009">HCC</term><def id="apt70183-li-0010"><p>hepatocellular carcinoma</p></def></def-item><def-item><term id="apt70183-li-0011">IHC</term><def id="apt70183-li-0012"><p>immunohistochemistry</p></def></def-item><def-item><term id="apt70183-li-0013">LT</term><def id="apt70183-li-0014"><p>liver transplantation</p></def></def-item><def-item><term id="apt70183-li-0015">MASH</term><def id="apt70183-li-0016"><p>Metabolic Associated Steatohepatitis</p></def></def-item><def-item><term id="apt70183-li-0017">PAS</term><def id="apt70183-li-0018"><p>Periodic Acid Schiff</p></def></def-item><def-item><term id="apt70183-li-0019">Pi&#8208;MM AAT</term><def id="apt70183-li-0020"><p>wild&#8208;type genotype</p></def></def-item><def-item><term id="apt70183-li-0021">Pi&#8208;MZ AAT</term><def id="apt70183-li-0022"><p>genotype with heterozygosity for the Pi&#8208;Z variant</p></def></def-item><def-item><term id="apt70183-li-0023">Pi&#8208;SZ AAT</term><def id="apt70183-li-0024"><p>genotype with compound heterozygosity for Pi&#8208;S and Pi&#8208;Z variants</p></def></def-item><def-item><term id="apt70183-li-0025">Pi&#8208;ZZ AAT</term><def id="apt70183-li-0026"><p>genotype with homozygosity for the Pi&#8208;Z variant</p></def></def-item></def-list><sec id="apt70183-sec-0005"><label>1</label><title>Introduction</title><p>Alpha&#8208;1 antitrypsin deficiency (AATD) is one of the most common hereditary disorders, characterised by reduced levels of alpha&#8208;1 antitrypsin (AAT), a protease inhibitor that protects lung tissue from neutrophil elastase&#8208;related damage [<xref rid="apt70183-bib-0001" ref-type="bibr">1</xref>, <xref rid="apt70183-bib-0002" ref-type="bibr">2</xref>]. Although AATD is more commonly associated with lung emphysema, its pathophysiology primarily involves the accumulation of abnormally folded AAT proteins in hepatocytes, leading to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [<xref rid="apt70183-bib-0003" ref-type="bibr">3</xref>, <xref rid="apt70183-bib-0004" ref-type="bibr">4</xref>, <xref rid="apt70183-bib-0005" ref-type="bibr">5</xref>]. Currently, liver transplantation (LT) is the only treatment available for severe hepatic manifestations.</p><p>Most of the population carries two wild&#8208;type alleles M of the SERPINA1 gene, which encodes AAT, resulting in normal blood protein levels. There are more than 100 allelic variants of SERPINA1, with the Z allele being the most common severe variant. The prevalence of AATD is variable, with the homozygous ZZ genotype (Pi&#8208;ZZ) being less common but more severe (1/2000 in Caucasians) and the heterozygous MZ genotype (Pi&#8208;MZ) representing a larger, often underdiagnosed population (1/30 individuals of Northern European descent) [<xref rid="apt70183-bib-0006" ref-type="bibr">6</xref>]. In a retrospective study including 1118 patients with ACLD, 4% of patients were found to carry the Pi&#8208;Z variant [<xref rid="apt70183-bib-0007" ref-type="bibr">7</xref>].</p><p>The Pi&#8208;MZ genotype is particularly intriguing in both children and adults [<xref rid="apt70183-bib-0005" ref-type="bibr">5</xref>]. Emerging literature suggests it acts as a cofactor in the progression of hepatic fibrosis, especially in the presence of other liver insults such as metabolic associated steatohepatitis (MASH) or chronic alcohol consumption [<xref rid="apt70183-bib-0008" ref-type="bibr">8</xref>, <xref rid="apt70183-bib-0009" ref-type="bibr">9</xref>]. This is highlighted by the observation that approximately 10% of liver transplant recipients in the Mayo Clinic cohort had Pi&#8208;MZ, suggesting a significant burden of disease within this population [<xref rid="apt70183-bib-0010" ref-type="bibr">10</xref>]. Moreover, individuals with Pi&#8208;MZ on the liver transplant waiting list showed a more rapid deterioration of their hepatic function [<xref rid="apt70183-bib-0011" ref-type="bibr">11</xref>]. In addition, patients with the Pi&#8208;ZZ genotype have a higher risk of cirrhosis&#8208;related complications and more rapid disease progression compared to other aetiologies, as highlighted in a recent study [<xref rid="apt70183-bib-0012" ref-type="bibr">12</xref>] This further supports the rationale for earlier listing of these patients for liver transplantation, underscoring the clinical importance of timely diagnosis.</p><p>Furthermore, the frequent association with cofactors complicates screening by practitioners, making AATD diagnosis difficult. The routine serum assay can be normal, particularly in Pi&#8208;MZ patients, and in inflammatory contexts, which are especially common in the pre&#8208;transplant setting. In this context, a 2020 American study showed that only 30% of liver transplant patients with AATD were diagnosed before transplantation [<xref rid="apt70183-bib-0013" ref-type="bibr">13</xref>].</p><p>In light of this and considering the highly variable prevalence of the disease worldwide, we aimed to: (1) assess the current state of pre&#8208;LT diagnosis of AATD in France and Canada and describe the clinical phenotype and diagnostic pathways amongst these patients and (2) explore the current knowledge and practices regarding AATD amongst French practitioners involved in LT to understand how this can influence diagnostics.</p></sec><sec id="apt70183-sec-0006"><label>2</label><title>Patients and Methods</title><p>First, we conducted a retrospective multicentre cohort study to evaluate the pretransplant diagnosis of AATD in patients undergoing LT and to study the clinical characteristics of these patients. Second, we conducted a national French survey to evaluate the current practices regarding AATD in the liver transplant community.</p><sec id="apt70183-sec-0007"><label>2.1</label><title>Retrospective Multicentre Cohort Study</title><p>This retrospective multicentre cohort study included LT candidates diagnosed with AATD based on Periodic Acid Schiff (PAS) positive staining of explanted livers from nine centres in France and Canada. The main inclusion criteria were as follows.</p><sec id="apt70183-sec-0008"><label>2.1.1</label><title>Clinical Criteria</title><p>Patients were required to have undergone liver transplantation between 1995 and 2020. Patients who were at least 18&#8201;years old at the time of LT were included. Patients who had PAS&#8208;positive staining on hepatic grafts following retransplantation were excluded from the study (Table&#160;<xref rid="apt70183-supitem-0001" ref-type="supplementary-material">S1</xref>).</p></sec><sec id="apt70183-sec-0009"><label>2.1.2</label><title>Histopathological Diagnosis</title><p>Patients were included if their explanted liver specimens showed at least one positive PAS staining of eosinophilic globules of varied size in the cytoplasm of periportal liver cells, indicating the presence of AATD. PAS staining was systematically performed on explanted liver specimens as soon as hyaline globules were observed with H&amp;E staining during the histological analysis of the explant at each participating centre, regardless of the clinical context. Immunohistochemistry (IHC) was systematically performed whenever PAS positive globules were identified, with IHC confirming positivity in 100% of cases. Confirmation of AATD diagnosis could also be achieved through phenotyping or genotyping when available, identifying specific AATD&#8208;related alleles such as Pi&#8208;Z (Glu342Lys), Pi&#8208;S (Glu264Val) or Pi&#8208;MMalton (&#916;52Phe). Phenotyping or genotyping was not available for all patients in the cohort, particularly those in the &#8216;undiagnosed&#8217; group. However, we were able to perform retrospective genotyping in one patient. Due to serum availability constraints and French legislation requiring patient consent, we were unable to conduct genotyping retrospectively for all patients.</p></sec><sec id="apt70183-sec-0010"><label>2.1.3</label><title>Data Collection</title><p>Each centre's pathology department was responsible for screening PAS staining of explant specimens. Patient data, including clinical characteristics, liver disease aetiology, and transplant&#8208;related data, were collected from medical records.</p><p>This retrospective, non&#8208;interventional study was conducted in accordance with the Declaration of Helsinki and principles of Good Clinical Practice.</p></sec></sec><sec id="apt70183-sec-0011"><label>2.2</label><title>Survey Analysis</title><p>A national survey was conducted amongst LT specialists in France to assess their knowledge, awareness, and practices regarding AATD following a practical guide [<xref rid="apt70183-bib-0014" ref-type="bibr">14</xref>]. The survey consisted of 22 questions designed to address the following key areas (Table&#160;<xref rid="apt70183-supitem-0001" ref-type="supplementary-material">S2</xref>): practitioner profiles to understand the demographic and professional background of the respondents, which could influence their knowledge and practices regarding AATD; knowledge and awareness of AATD to gauge the overall awareness and understanding of AATD amongst LT specialists, which is crucial for identifying gaps in knowledge that could contribute to underdiagnosis; screening practices to evaluate current screening practices and identify potential areas for improvement in the diagnostic process of AATD; clinical management to assess how AATD patients are managed post&#8208;diagnosis and to identify any inconsistencies or areas for enhancement of patient care; impact of recent research to determine if recent research findings have been integrated into clinical practice, reflecting the responsiveness of practitioners to emerging evidence; and post&#8208;transplant screening and management to understand post&#8208;transplant diagnostic and management practices, which are essential for improving long&#8208;term outcomes in AATD patients.</p><p>The questionnaire was distributed with the help of the GREF&#8208;2 mailing list. This mailing list includes physicians actively involved in LT in France. Not all practitioners are part of this GREF&#8208;2 group, but it includes the most engaged in clinical research. This mailing list covers all liver transplant centres in France, ensuring broad institutional representation. The questionnaire was sent via an online platform (web&#8208;based Google Forms Survey) to 99 hepatologists, anaesthesiologists invested in LT, or digestive surgeons throughout France. Two reminders were sent over a two&#8208;month period. Participation was voluntary, and no incentives were offered.</p></sec><sec id="apt70183-sec-0012"><label>2.3</label><title>Statistical Analysis</title><p>Descriptive statistics were employed to summarise characteristics of patients and responses from the survey.</p><p>Qualitative variables were analysed using the chi&#8208;squared test or Fisher's exact test for datasets with small sample sizes and are expressed as <italic toggle="yes">N</italic> (%). Quantitative variables were assessed using the t student or the Mann&#8211;Whitney <italic toggle="yes">U</italic> test for datasets with small sample sizes and are expressed as mean&#8201;&#177;&#8201;SD. In cases involving three groups, the non&#8208;parametric one&#8208;way ANOVA test (Kruskal&#8211;Wallis test) was applied with multiple comparisons, and Fisher's exact test was used for smaller sample sizes.</p><p>Statistical significance was defined by a <italic toggle="yes">p</italic>&#8208;value of less than 0.05 for all objectives. Statistical analyses were conducted using <italic toggle="yes">p</italic>&#8208;value Io software (<italic toggle="yes">p</italic>&#8208;value.io).</p></sec></sec><sec sec-type="results" id="apt70183-sec-0013"><label>3</label><title>Results</title><sec id="apt70183-sec-0014"><label>3.1</label><title>Diagnosis of <styled-content style="fixed-case" toggle="no">AATD</styled-content> in Our Retrospective Multicentric Cohort</title><sec id="apt70183-sec-0015"><label>3.1.1</label><title>Patient Characteristics and <styled-content style="fixed-case" toggle="no">LT</styled-content> Outcomes</title><p>We enrolled 58 patients from nine French and Canadian centres. The average age was 55.6&#8201;&#177;&#8201;9.9&#8201;years at the time of LT, and 45 (78%) patients were male. Regarding cirrhosis complications before LT, 29 (50%) patients had ascites, 9 (15.5%) had spontaneous bacterial peritonitis, 38 (66%) had hepatic encephalopathy, and 14 (24%) had gastrointestinal bleeding due to rupture of oesophageal varices (Table&#160;<xref rid="apt70183-tbl-0001" ref-type="table">1</xref>). The mean MELD score at LT was 24.1&#8201;&#177;&#8201;8.8. The indication for transplantation was decompensated cirrhosis in 53 (91.4%) patients and HCC in 5 (8.6%) patients (Table&#160;<xref rid="apt70183-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="apt70183-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>58 patients characteristics according to their genetic status.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Data available <italic toggle="yes">N</italic>&#8201;=&#8201;58</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total cohort <italic toggle="yes">N</italic>&#8201;=&#8201;58</th><th align="center" valign="bottom" rowspan="1" colspan="1">Homozygous Pi&#8208;ZZ <italic toggle="yes">N</italic>&#8201;=&#8201;10 (17%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Heterozygous Pi&#8208;SZ Pi&#8208;MZ Pi&#8208;M<sub>Malton</sub>
<italic toggle="yes">N</italic>&#8201;=&#8201;16 (27%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Male gender, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">45 (78.0)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (70.0)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (75.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age at LT, mean&#8201;&#177;&#8201;SD</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">55.6&#8201;&#177;&#8201;9.96</td><td align="center" valign="top" rowspan="1" colspan="1">51.5&#8201;&#177;&#8201;9.61</td><td align="center" valign="top" rowspan="1" colspan="1">60.6&#8201;&#177;&#8201;4.65</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Main aetiology of cirrhosis, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="5" valign="top" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" rowspan="5" valign="top" colspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Alpha 1 antitrypsin deficiency</td><td align="center" valign="top" rowspan="1" colspan="1">18 (31.0)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (100)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (31.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Chronic alcohol consumption</td><td align="center" valign="top" rowspan="1" colspan="1">25 (43.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (44.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">MASH</td><td align="center" valign="top" rowspan="1" colspan="1">8 (14.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (6.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cryptogenic</td><td align="center" valign="top" rowspan="1" colspan="1">7 (12.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (19.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">34 (59.0)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (40.0)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (56.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alcohol consumption&#8201;&gt;&#8201;50&#8201;g/day &gt;&#8201;5&#8201;years, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">52<xref rid="apt70183-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">14 (27.0)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (20.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), mean&#8201;&#177;&#8201;SD</td><td align="center" valign="top" rowspan="1" colspan="1">55<xref rid="apt70183-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">26.3&#8201;&#177;&#8201;5.76</td><td align="center" valign="top" rowspan="1" colspan="1">23.7&#8201;&#177;&#8201;4.16</td><td align="center" valign="top" rowspan="1" colspan="1">25.7&#8201;&#177;&#8201;4.87</td><td align="center" valign="top" rowspan="1" colspan="1">0.30</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Type 2 diabetes, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">57</td><td align="center" valign="top" rowspan="1" colspan="1">17 (30.0)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (20.0)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (27.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gastrointestinal bleeding due to rupture of EV, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">14 (24.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (10.0)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (31.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hepatic encephalopathy, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">38 (66.0)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (70.0)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (56.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Oedematous ascitic decompensation, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">54 (93.0)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (80.0)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (94.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Spontaneous bacterial peritonitis, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">19 (33.0)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (30.0)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (31.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Refractory ascites, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">29 (50.0)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (40.0)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (50.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hepatocellular carcinoma, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">14 (24.1)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (50.0)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (19.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pulmonary emphysema, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">5 (8.6)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (30.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (6.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cough, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">2 (3.4)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (20.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dyspnoea, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">11 (19.0)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (30.0)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (12.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Respiratory function tests, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="4" valign="top" colspan="1">43</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" rowspan="4" valign="top" colspan="1">0.26</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Normal</td><td align="center" valign="top" rowspan="1" colspan="1">29 (67.0)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (50.0)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (82.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Obstructive ventilatory syndrome</td><td align="center" valign="top" rowspan="1" colspan="1">7 (16.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (10.0)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (18.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Restrictive ventilatory syndrome</td><td align="center" valign="top" rowspan="1" colspan="1">7 (16.5)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (20.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lung transplantation, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.7)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (10.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Augmentation therapy for AAT, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Family history of emphysema, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">3 (6.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (12.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Intracerebral aneurysm, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.7)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (10.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diagnosis of AATD at LT, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="4" valign="top" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" rowspan="4" valign="top" colspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Before LT</td><td align="center" valign="top" rowspan="1" colspan="1">23 (40.0)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (100)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (44.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">After LT</td><td align="center" valign="top" rowspan="1" colspan="1">9 (15.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (56.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Undiagnosed</td><td align="center" valign="top" rowspan="1" colspan="1">26 (45.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pre&#8208;LT serum level, mg/ml, mean&#8201;&#177;&#8201;SD</td><td align="center" valign="top" rowspan="1" colspan="1">35<xref rid="apt70183-note-0007" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.68&#8201;&#177;&#8201;0.32</td><td align="center" valign="top" rowspan="1" colspan="1">0.36&#8201;&#177;&#8201;0.21</td><td align="center" valign="top" rowspan="1" colspan="1">0.82&#8201;&#177;&#8201;0.27</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot id="apt70183-ntgp-0002"><fn id="apt70183-note-0003"><p>
<italic toggle="yes">Note:</italic> The comparison was made between homozygous and heterozygous patients.</p></fn><fn id="apt70183-note-0004"><p>Abbreviations: AAT, alpha1&#8208; antitrypsin; AATD, alpha1&#8208;antitrypsin deficiency; BMI, body mass index; LT, liver transplantation; OV, oesophageal varices.</p></fn><fn id="apt70183-note-0005"><label>
<sup>a</sup>
</label><p>Two missing data points in the homozygous patient group, one missing data point in the heterozygous group.</p></fn><fn id="apt70183-note-0006"><label>
<sup>b</sup>
</label><p>Two missing data points in the heterozygous patient group.</p></fn><fn id="apt70183-note-0007"><label>
<sup>c</sup>
</label><p>One missing data point in each group.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="apt70183-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Conditions at LT and post&#8208;LT of the 58 patients according to their genetic status.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Data available <italic toggle="yes">N</italic>&#8201;=&#8201;58</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total cohort <italic toggle="yes">N</italic>&#8201;=&#8201;58</th><th align="center" valign="bottom" rowspan="1" colspan="1">Homozygous Pi&#8208;ZZ <italic toggle="yes">N</italic>&#8201;=&#8201;10 (17%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Heterozygous Pi&#8208;SZ Pi&#8208;MZ Pi&#8208;MMalton <italic toggle="yes">N</italic>&#8201;=&#8201;16 (27%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Hospitalisation at LT, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">23 (40.0)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (50.0)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (31.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ICU admission in the month prior to LT, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">13 (22.0)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (30.0)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (25.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACLF, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">12 (21.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (10.0)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (38.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hepatic encephalopathy, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">28 (48.0)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (40.0)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (56.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sepsis, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">17 (29.0)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (50.0)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (12.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.069</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Respiratory pathology, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">17 (27.0)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (30.0)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (19.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">OAD, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">41 (71.0)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (70.0)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (75.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MELD score at LT, mean&#8201;&#177;&#8201;SD</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">24.1&#8201;&#177;&#8201;8.81</td><td align="center" valign="top" rowspan="1" colspan="1">27.3&#8201;&#177;&#8201;9.65</td><td align="center" valign="top" rowspan="1" colspan="1">22.5&#8201;&#177;&#8201;9.35</td><td align="center" valign="top" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LT indication, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="3" valign="top" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" rowspan="3" valign="top" colspan="1">0.26</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cirrhosis</td><td align="center" valign="top" rowspan="1" colspan="1">53 (91.4)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (100)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (81.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">HCC</td><td align="center" valign="top" rowspan="1" colspan="1">5 (8.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (19.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Time from listing to LT, months, mean&#8201;&#177;&#8201;SD</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">4.7&#8201;&#177;&#8201;6.2</td><td align="center" valign="top" rowspan="1" colspan="1">6.1&#8201;&#177;&#8201;10.23</td><td align="center" valign="top" rowspan="1" colspan="1">4.43&#8201;&#177;&#8201;3.53</td><td align="center" valign="top" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MELD change between listing and LT, mean&#8201;&#177;&#8201;SD</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">2.21&#8201;&#177;&#8201;5.00</td><td align="center" valign="top" rowspan="1" colspan="1">2.40&#8201;&#177;&#8201;5.44</td><td align="center" valign="top" rowspan="1" colspan="1">1.12&#8201;&#177;&#8201;5.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Post&#8208;LT pulmonary infection, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">15 (26.0)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (30.0)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (19.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Post&#8208;LT acute renal failure, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">23 (40.0)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (30.0)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (44.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ICU stay&#8201;&gt;&#8201;10&#8201;days or return to ICU, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">20 (34.0)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (60.0)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (25.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Days in ICU post&#8208;LT, mean&#8201;&#177;&#8201;SD</td><td align="center" valign="top" rowspan="1" colspan="1">55<xref rid="apt70183-note-0010" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">12.6&#8201;&#177;&#8201;30</td><td align="center" valign="top" rowspan="1" colspan="1">21.3&#8201;&#177;&#8201;41.6</td><td align="center" valign="top" rowspan="1" colspan="1">8.69&#8201;&#177;&#8201;20.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Days of oro&#8208;tracheal intubation post&#8208;LT, mean&#8201;&#177;&#8201;SD</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">8.38&#8201;&#177;&#8201;24.3</td><td align="center" valign="top" rowspan="1" colspan="1">14.3&#8201;&#177;&#8201;37.2</td><td align="center" valign="top" rowspan="1" colspan="1">2.19&#8201;&#177;&#8201;0.75</td><td align="center" valign="top" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rejection, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">6 (10.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (10.0)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (12.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Liver retransplantation, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">3 (5.2)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (20.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Death, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">5 (8.6)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (10.0)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (12.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot id="apt70183-ntgp-0003"><fn id="apt70183-note-0008"><p>
<italic toggle="yes">Note:</italic> The comparison was made between homozygous and heterozygous patients.</p></fn><fn id="apt70183-note-0009"><p>Abbreviations: ACLF, acute on chronic liver failure; ICU, intensive care unit; LT, liver transplantation; OAD, oedematous ascitic decompensation.</p></fn><fn id="apt70183-note-0010"><label>
<sup>a</sup>
</label><p>One missing data point in the homozygous patient group.</p></fn></table-wrap-foot></table-wrap><p>In our cohort of 58 AATD patients, less than 25% displayed non&#8208;specific pulmonary symptoms, such as cough (3.4%) and dyspnoea (19%). Additionally, five patients (8.6%) had emphysema, all of whom were smokers, and three (5.1%) had a family history of emphysema. Only one patient underwent lung transplantation for AATD, and none received augmentation therapy for AATD. There were no recorded cases of panniculitis, ANCA&#8208;associated vasculitis, or glomerulopathy, except for one instance of an intracerebral aneurysm in a homozygous patient (Table&#160;<xref rid="apt70183-tbl-0001" ref-type="table">1</xref>). The mortality rate in the present study was 8.6% (Table&#160;<xref rid="apt70183-tbl-0002" ref-type="table">2</xref>).</p></sec><sec id="apt70183-sec-0016"><label>3.1.2</label><title>Diagnosis of Alpha&#8208;1 Antitrypsin Deficiency: Timing and Methods</title><p>AATD was diagnosed pre&#8208;LT in only 40% of cases; for the 60% undiagnosed pre&#8208;LT, diagnosis was confirmed post&#8208;LT in 15% and remained unconfirmed in 45% of cases (Table&#160;<xref rid="apt70183-tbl-0001" ref-type="table">1</xref>). Of the 23 (40%) patients diagnosed prior to LT, most (78%) had undergone transplantation for AATD as the main indication, while the others were considered to have AATD as a cofactor. Diagnosis was made in 78% of the cases by phenotyping or genotyping, and 50% were homozygous. For the other 5 patients (22%) diagnosis was made by the association of a low pre&#8208;LT serum AAT level with a liver biopsy with PAS +. Interestingly, 60% of patients diagnosed pre&#8208;LT had a pre&#8208;LT liver biopsy, with 93% of the cases positive for PAS. Serum assays were performed in 87% of cases and averaged 0.6&#8201;mg/mL&#8201;&#177;&#8201;0.34 (Table&#160;<xref rid="apt70183-tbl-0003" ref-type="table">3</xref>).</p><table-wrap position="float" id="apt70183-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Influence of the timing and methods of AATD diagnosis amongst the 58 patients.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Data available <italic toggle="yes">N</italic>&#8201;=&#8201;58</th><th align="center" valign="bottom" rowspan="1" colspan="1">Pre&#8208;LT diagnosis <italic toggle="yes">N</italic>&#8201;=&#8201;23 (40%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Post&#8208;LT diagnosis <italic toggle="yes">N</italic>&#8201;=&#8201;9 (15%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Undiagnosed <italic toggle="yes">N</italic>&#8201;=&#8201;26 (45%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Male gender, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">15 (65.0)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (100)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (81.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age at LT, mean&#8201;&#177;&#8201;SD</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">53.5&#8201;&#177;&#8201;10.9</td><td align="center" valign="top" rowspan="1" colspan="1">61.1&#8201;&#177;&#8201;5.37</td><td align="center" valign="top" rowspan="1" colspan="1">55.4&#8201;&#177;&#8201;9.89</td><td align="center" valign="top" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Main aetiology of cirrhosis, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="5" valign="top" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" rowspan="5" valign="top" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Alpha 1 antitrypsin deficiency</td><td align="center" valign="top" rowspan="1" colspan="1">18 (78.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Chronic alcohol consumption</td><td align="center" valign="top" rowspan="1" colspan="1">3 (13.0)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (67.0)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (62.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">MASH</td><td align="center" valign="top" rowspan="1" colspan="1">1 (4.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (11.0)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (23.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cryptogenic</td><td align="center" valign="top" rowspan="1" colspan="1">1 (4.5)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (22.0)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (15.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">9 (39.0)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (78.0)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (69.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alcohol consumption&#8201;&gt;&#8201;50&#8201;g/day &gt;&#8201;5&#8201;years, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">52</td><td align="center" valign="top" rowspan="1" colspan="1">3 (15.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (48.0)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Phenotyping or Genotyping, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="6" valign="top" colspan="1">28</td><td align="center" valign="top" rowspan="1" colspan="1">19 (82.0)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (100)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PI&#8208;ZZ</td><td align="center" valign="top" rowspan="1" colspan="1">10 (43.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="5" valign="top" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PI&#8208;SZ</td><td align="center" valign="top" rowspan="1" colspan="1">2 (8.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PI&#8208;MZ</td><td align="center" valign="top" rowspan="1" colspan="1">4 (17.0)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (100)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PI&#8208;M<sub>Malton</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Missing data</td><td align="center" valign="top" rowspan="1" colspan="1">2 (8.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pre&#8208;LT serum level, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="2" valign="top" colspan="1">35</td><td align="center" valign="top" rowspan="1" colspan="1">20 (87.0)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (89.0)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (27.0)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Level, mg/ml, mean&#8201;&#177;&#8201;SD</td><td align="center" valign="top" rowspan="1" colspan="1">0.60&#8201;&#177;&#8201;0.34</td><td align="center" valign="top" rowspan="1" colspan="1">0.80&#8201;&#177;&#8201;0.25</td><td align="center" valign="top" rowspan="1" colspan="1">0.81&#8201;&#177;&#8201;0.30</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pre&#8208;LT liver biopsy, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="3" valign="top" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">14 (60.0)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (22.0)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (19.0)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PAS+</td><td align="center" valign="top" rowspan="1" colspan="1">13 (93.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No PAS+</td><td align="center" valign="top" rowspan="1" colspan="1">1 (7.1)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (100.0)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (100.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MELD score at LT, mean&#8201;&#177;&#8201;SD</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">24&#8201;&#177;&#8201;8.1</td><td align="center" valign="top" rowspan="1" colspan="1">23.1&#8201;&#177;&#8201;11.2</td><td align="center" valign="top" rowspan="1" colspan="1">24.6&#8201;&#177;&#8201;8.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LT indication, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="3" valign="top" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" rowspan="3" valign="top" colspan="1">0.29</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cirrhosis</td><td align="center" valign="top" rowspan="1" colspan="1">22 (96.0)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (78.0)</td><td align="center" valign="top" rowspan="1" colspan="1">24 (92.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">HCC</td><td align="center" valign="top" rowspan="1" colspan="1">1 (4.3)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (22.0)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (7.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Death, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">2 (8.7)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (11.0)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (7.7)</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot id="apt70183-ntgp-0004"><fn id="apt70183-note-0011"><p>
<italic toggle="yes">Note:</italic> The comparison was made between pre&#8208;LT diagnosis, post&#8208;LT diagnosis and undiagnosed patients.</p></fn><fn id="apt70183-note-0012"><p>Abbrevitaion: LT, liver transplantation.</p></fn></table-wrap-foot></table-wrap><p>For the nine (15%) patients diagnosed with AATD post&#8208;LT, diagnosis was always confirmed by phenotyping or genotyping, and all were heterozygous Pi&#8208;MZ. In the post&#8208;LT diagnosis and undiagnosed groups, 7 (20%) patients had a pre&#8208;LT biopsy that did not reveal PAS positivity, complicating the diagnosis. Moreover, 8 (89%) patients in the post&#8208;LT diagnostic group and 7 (27%) in the undiagnosed group had low pre&#8208;LT serum AAT levels averaging 0.8&#8201;&#177;&#8201;0.25 and 0.81&#8201;&#177;&#8201;0.31 respectively, but without a diagnosis (Table&#160;<xref rid="apt70183-tbl-0003" ref-type="table">3</xref>).</p><p>Furthermore, we identified differences in practice between the centres. Most patients diagnosed with post&#8208;LT (67%) were managed at the University Hospital of Lyon (AATD Reference Centre), whereas for other transplant centres, patients who were not diagnosed with pre&#8208;LT were also not diagnosed with post&#8208;LT (Table&#160;<xref rid="apt70183-supitem-0001" ref-type="supplementary-material">S3</xref>).</p><p>The indications for LT in our cohort were 31% for cirrhosis due to AATD, 43% for alcoholic liver disease, 14% for MASH cirrhosis and 12% for cryptogenic cirrhosis (Table&#160;<xref rid="apt70183-tbl-0001" ref-type="table">1</xref>). Interestingly, patients diagnosed with post&#8208;LT or undiagnosed were transplanted in 67% and 62% of the cases, respectively, for chronic alcohol consumption, although a minority had a consumption of more than 50&#8201;g/day for over 5&#8201;years. They were also transplanted in 11% and 23% of patients with MASH cirrhosis and in 22% and 15% of patients with cryptogenic cirrhosis, respectively (Table&#160;<xref rid="apt70183-tbl-0003" ref-type="table">3</xref>).</p><p>We investigated the potential impact of time on the genotyping/phenotyping of patients. A timeline analysis was performed using five&#8208;year intervals over our study period to assess the year of genotyping/phenotyping when available for patients (<italic toggle="yes">N</italic>&#8201;=&#8201;26). It was analysed whether patients were diagnosed before or after LT. Amongst patients diagnosed before LT, 10 (58%) underwent testing between 1995 and 2005, and 7 (42%) between 2005 and 2020. In contrast, amongst those diagnosed after LT, 6 (66%) had their genotyping/phenotyping test between 2015 and 2020 (Table&#160;<xref rid="apt70183-supitem-0001" ref-type="supplementary-material">S4</xref>).</p></sec><sec id="apt70183-sec-0017"><label>3.1.3</label><title>Homozygous or Heterozygous Phenotypes: Two Different Situations</title><p>Although only 44% of the patients in the cohort had available phenotyping or genotyping, we found significant differences between homozygous and heterozygous patients. There were ten (17%) patients in the homozygous group (Pi&#8208;ZZ) and 16 (27%) patients in the heterozygous group (Pi&#8208;SZ, Pi&#8208;MZ, and Pi&#8208;MMalton). Patients with the heterozygous phenotype were significantly older at the time of transplantation than the homozygous patients (60.6 vs. 51.5&#8201;years, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01). All homozygous patients were transplanted for AATD compared to 31% of heterozygous patients (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01), with a pre&#8208;transplant diagnosis in 100% of cases compared to 44% of heterozygous patients (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01). Heterozygous patients more often had a cofactor for cirrhosis and had been transplanted in 44% of patients with cirrhosis due to excessive alcohol consumption, 6% for MASH, and 19% for cryptogenic cirrhosis. Pre&#8208;transplant serum levels were significantly lower in homozygous patients compared to heterozygous patients (0.36 vs. 0.82&#8201;mg/mL, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01) (Table&#160;<xref rid="apt70183-tbl-0001" ref-type="table">1</xref>).</p></sec></sec><sec id="apt70183-sec-0018"><label>3.2</label><title>Current State of Knowledge and Practices&#8212;National French Survey Analysis</title><p>The survey retrieved 59 responses (59% response rate), primarily from gastroenterologists (89.8%), with the rest being from hepatobiliary surgeons (6.8%) and anaesthesiologist&#8208;intensivists (3.4%), mostly from university hospitals (94.9%). A significant proportion (52.5%) had more than 15&#8201;years of experience in LT and managed more than 50 LT patients annually (50.8%). Most practitioners underestimated the prevalence of AATD in their patients, with 27.1% estimating none, 54.2% less than 2%, and 18.6% between 2% to 5% (Table&#160;<xref rid="apt70183-supitem-0001" ref-type="supplementary-material">S2</xref>). Knowledge levels were low, with 78% rating their understanding as very low to average, and only 22% correctly answering prevalence&#8208;related questions. The role of homozygous AATD as a chronic liver disease factor was recognised as very strong or strong by 66.1% of practitioners; however, the contribution of heterozygous AATD was considered ineffective, low or very low (56%).</p><p>Heterozygous deficiency has recently been attributed as a cofactor of cirrhosis in cases of MASH or alcohol consumption; however, only 49.2% of practitioners have changed their practice following these publications (Table&#160;<xref rid="apt70183-tbl-0004" ref-type="table">4</xref>). Regarding progression on the transplant list, 20.3% of practitioners felt that their patients with AATD deteriorated more rapidly than others, whereas 13.6% did not perceive a difference in the worsening of cirrhotic patients due to other aetiologies. However, 66.1% were either unaware of or not confronted with this situation (Table&#160;<xref rid="apt70183-supitem-0001" ref-type="supplementary-material">S2</xref>).</p><table-wrap position="float" id="apt70183-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Responses from 59 LT practitioners to the national survey.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Questions</th><th align="center" valign="bottom" rowspan="1" colspan="1">Answers (<italic toggle="yes">N</italic>&#8201;=&#8201;59)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic> (%)</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="6" valign="top" colspan="1">In your opinion, what is your level of knowledge regarding alpha 1 anti&#8208;trypsin deficiency (AATD)?</td><td align="center" valign="top" rowspan="1" colspan="1">Very low</td><td align="center" valign="top" rowspan="1" colspan="1">6 (10.2)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Low</td><td align="center" valign="top" rowspan="1" colspan="1">12 (20.3)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Average</td><td align="center" valign="top" rowspan="1" colspan="1">28 (47.5)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Good</td><td align="center" valign="top" rowspan="1" colspan="1">12 (20.3)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Very good</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.7)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">I don't know</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" rowspan="5" valign="top" colspan="1">The prevalence of AATD in France (homozygous or heterozygous) is:</td><td align="center" valign="top" rowspan="1" colspan="1">About 1/100</td><td align="center" valign="top" rowspan="1" colspan="1">2 (3.4)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">1/1000</td><td align="center" valign="top" rowspan="1" colspan="1">13 (22.0)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">1/10000</td><td align="center" valign="top" rowspan="1" colspan="1">27 (45.8)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">1/100,000</td><td align="center" valign="top" rowspan="1" colspan="1">9 (15.3)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">I don't know</td><td align="center" valign="top" rowspan="1" colspan="1">8 (13.6)</td></tr><tr><td align="left" rowspan="7" valign="top" colspan="1">In your opinion, what is the role of heterozygous AATD as a factor in chronic liver disease?</td><td align="center" valign="top" rowspan="1" colspan="1">Very strong</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.7)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Strong</td><td align="center" valign="top" rowspan="1" colspan="1">2 (3.4)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Average</td><td align="center" valign="top" rowspan="1" colspan="1">22 (37.3)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Weak</td><td align="center" valign="top" rowspan="1" colspan="1">21 (35.6)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Very weak</td><td align="center" valign="top" rowspan="1" colspan="1">8 (13.6)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">4 (6.8)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">I don't know</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.7)</td></tr><tr><td align="left" rowspan="5" valign="top" colspan="1">Several recent studies have proven the impact of heterozygous AATD as a cofactor for cirrhosis in cases of MASH or associated excessive alcohol consumption. Has this changed your practice?</td><td align="center" valign="top" rowspan="1" colspan="1">Yes, it is</td><td align="center" valign="top" rowspan="1" colspan="1">5 (8.5)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Yes, partially</td><td align="center" valign="top" rowspan="1" colspan="1">24 (40.7)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Not at all</td><td align="center" valign="top" rowspan="1" colspan="1">18 (30.5)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">I am not aware of this information</td><td align="center" valign="top" rowspan="1" colspan="1">11 (18.6)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">I don't know</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.7)</td></tr><tr><td align="left" rowspan="4" valign="top" colspan="1">In a pre&#8208;transplant context, have you experienced a faster deterioration in patients with AATD compared to unaffected patients?</td><td align="center" valign="top" rowspan="1" colspan="1">Rather not</td><td align="center" valign="top" rowspan="1" colspan="1">8 (13.6)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Quite yes</td><td align="center" valign="top" rowspan="1" colspan="1">12 (20.3)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">I don't know</td><td align="center" valign="top" rowspan="1" colspan="1">16 (27.1)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">I don't have the experience</td><td align="center" valign="top" rowspan="1" colspan="1">23 (39.0)</td></tr><tr><td align="left" rowspan="4" valign="top" colspan="1">In what context do you perform pre&#8208;transplant AATD screening?</td><td align="center" valign="top" rowspan="1" colspan="1">Systematically</td><td align="center" valign="top" rowspan="1" colspan="1">35 (59.3)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Cirrhosis of undetermined cause</td><td align="center" valign="top" rowspan="1" colspan="1">20 (33.9)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Rarely</td><td align="center" valign="top" rowspan="1" colspan="1">2 (3.4)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Never</td><td align="center" valign="top" rowspan="1" colspan="1">2 (3.4)</td></tr><tr><td align="left" rowspan="5" valign="top" colspan="1">In this case, what screening method do you use? (several answers possible)</td><td align="center" valign="top" rowspan="1" colspan="1">Serum AAT assay</td><td align="center" valign="top" rowspan="1" colspan="1">54 (94.7)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Phenotyping</td><td align="center" valign="top" rowspan="1" colspan="1">12 (21.1)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Genotyping</td><td align="center" valign="top" rowspan="1" colspan="1">5 (8.8)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Liver biopsy for PAS+</td><td align="center" valign="top" rowspan="1" colspan="1">6 (10.5)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Other</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1.7)</td></tr><tr><td align="left" rowspan="4" valign="top" colspan="1">In your opinion, what serum AAT level is compatible with the implication of AATD as a chronic liver disease? (several answers possible)</td><td align="center" valign="top" rowspan="1" colspan="1">&lt;&#8201;0.5&#8201;g/L</td><td align="center" valign="top" rowspan="1" colspan="1">42 (72.4)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">0.5&#8211;1.1&#8201;g/L</td><td align="center" valign="top" rowspan="1" colspan="1">28 (48.3)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">&gt;&#8201;1.1&#8201;g/l</td><td align="center" valign="top" rowspan="1" colspan="1">2 (3.4)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">I don't know</td><td align="center" valign="top" rowspan="1" colspan="1">9 (15.5)</td></tr><tr><td align="left" rowspan="4" valign="top" colspan="1">In the event of PAS+&#8201;on an explanted liver, do you carry out AATD screening post liver transplant?</td><td align="center" valign="top" rowspan="1" colspan="1">Always</td><td align="center" valign="top" rowspan="1" colspan="1">24 (40.7)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Sometimes</td><td align="center" valign="top" rowspan="1" colspan="1">8 (13.6)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Never</td><td align="center" valign="top" rowspan="1" colspan="1">5 (8.5)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">I'm not faced with this situation</td><td align="center" valign="top" rowspan="1" colspan="1">22 (37.3)</td></tr></tbody></table></table-wrap><p>Concerning screening practices in the pre&#8208;LT context, 59.3% of practitioners routinely performed screening, 33.9% conducted screening only if cirrhosis was of undetermined cause, and 6.8% rarely or never screened. Interestingly, serum testing was used in 94.7% of these screenings, but its interpretation remained relatively unknown (Table&#160;<xref rid="apt70183-tbl-0004" ref-type="table">4</xref>). Most practitioners are only somewhat aware of the factors that can influence the level; 46.6% know that it is decreased by cellular insufficiency and 20.7% by pregnancy. The impact of infection and inflammation was better understood (62.1%). Additionally, only 3.4% of practitioners considered that a normal AAT level is compatible with chronic liver disease. In the pre&#8208;LT context, genetic research through phenotyping or genotyping was carried out by 29.9% of practitioners. One limitation of this method is its accessibility in clinical practice; however, 54.2% of practitioners find this access within the hospital simple to achieve, and 18.6% find it accessible but difficult (Table&#160;<xref rid="apt70183-supitem-0001" ref-type="supplementary-material">S2</xref>).</p><p>Regarding screening practices in the post&#8208;LT context, in the case of discovery of PAS+ on liver explants, 40.7% systematically screened for AATD, 13.6% screened for it occasionally, and 8.5% never screened for it (Table&#160;<xref rid="apt70183-tbl-0004" ref-type="table">4</xref>). Regarding the clinical management of AATD patients, most referred them to pulmonologists (91.5%), with only 13.6% maintaining standard follow&#8208;up and 13.6% referring to specialised hepatologists. Family screening was performed by 52.5% of the respondents. While 74.6% regarded LT as a treatment for liver disease associated with AATD, less than 35% were aware of the new treatments under study (Table&#160;<xref rid="apt70183-supitem-0001" ref-type="supplementary-material">S3</xref>).</p></sec></sec><sec sec-type="discussion" id="apt70183-sec-0019"><label>4</label><title>Discussion</title><p>We conducted the first multicentre cohort study in France and Canada, revealing a significant underdiagnosis of AATD in LT candidates. Amongst the 58 patients, only 40% were diagnosed with AATD before LT, highlighting the major gaps in pre&#8208;transplant screening practices. Despite satisfactory post&#8208;LT outcomes with no excess pulmonary complications, this underdiagnosis is likely due to significant gaps in awareness amongst LT specialists, as our survey results indicate. A similar U.S. study reported a 30% pre&#8208;LT diagnosis rate for AATD in 117 patients, confirming that this issue is widespread [<xref rid="apt70183-bib-0013" ref-type="bibr">13</xref>].</p><p>Diagnosing AATD, particularly in heterozygous patients, is challenging, yet it significantly affects survival and the chances of undergoing transplantation [<xref rid="apt70183-bib-0007" ref-type="bibr">7</xref>]. The serum AAT assay, although inexpensive and easy to perform, is difficult to interpret due to factors such as inflammation and infection, which are common in cirrhotic patients. This complexity was poorly understood by 62% of the practitioners in our survey. Serum levels were significantly lower in the homozygous patients than in the heterozygous patients (0.36 vs. 0.82&#8201;mg/mL, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01). Notably, four patients had normal levels, which is consistent with what is known about heterozygous patients whose levels may be normal [<xref rid="apt70183-bib-0015" ref-type="bibr">15</xref>]. Genotyping is the most reliable diagnostic method [<xref rid="apt70183-bib-0006" ref-type="bibr">6</xref>]. It may seem that it is not widely accessible in daily practice; however, this hypothesis is not supported by our survey analysis since more than 50% of our survey respondents had access to genotyping in their own hospitals. The primary limiting factor for diagnosis appears to be the lack of awareness of AATD, especially in the presence of cofactors of liver disease. Better awareness of the disease could lead to a higher diagnosis rate, as in our cohort results where there is a higher frequency of post&#8208;LT diagnoses in Lyon, the national reference centre for AATD. It also seems difficult to determine when to perform genotyping, particularly in cases with normal serum levels&#8212;such as during infection or in heterozygous patients. A more detailed practice survey would be valuable to refine diagnostic strategies. For instance, we could have included a question in our survey asking whether clinicians systematically test all MASH or ALD patients or only those who are younger. Developing a pre&#8208;LT serum AAT threshold associated with MELD and CRP levels may also be beneficial.</p><p>Liver biopsy for PAS+ staining, while specific for AATD, is invasive and is not always feasible. In our cohort, 60% of the patients diagnosed with pre&#8208;LT had liver biopsies, with only one being PAS&#8208;negative, whereas in the post&#8208;LT diagnosed or undiagnosed groups, 20% had biopsies, all of which were PAS&#8208;negative, complicating the diagnosis. One limitation of this study is the absence of centralised PAS staining review, and not all patients underwent genotyping. Nevertheless, PAS staining is a standard technique, and PAS&#8208;positive hyaline globules are highly characteristic. Immunohistochemistry was systematically performed when PAS&#8208;positive globules were seen, enhancing specificity. In a recent US cohort, 11% of liver explants had PAS&#8208;positive globules; all were IHC&#8208;positive, and 85% carried the Z or S allele. Other rare alleles (e.g., Pi&#8208;MMalton) were not investigated, possibly explaining the remaining cases&#160;[<xref rid="apt70183-bib-0016" ref-type="bibr">16</xref>]. Restricting PAS staining to cases with hyaline globules on H&amp;E may have led to missed diagnoses, especially amongst PiMZ individuals. In Schneider's study, H&amp;E staining showed inclusions in 10.7% of PiMZ biopsies (<italic toggle="yes">n</italic>&#8201;=&#8201;84), with 40.5% being PAS&#8208;positive [<xref rid="apt70183-bib-0015" ref-type="bibr">15</xref>]. Ideally, centralised blinded H&amp;E review, followed by PAS and genotyping, would have improved diagnostic accuracy. However, this was not feasible due to logistical and regulatory constraints&#8212;given the 25&#8208;year period, decentralised pathology, and limits on retrospective genetic testing in France. Importantly, the aim of this study was not to estimate AATD prevalence, but to illustrate underdiagnosis and variability in diagnostic practices across centres.</p><p>Our survey revealed significant gaps in awareness and interest amongst the LT specialists. Only 50% of the patients were systematically screened for AATD pre&#8208;LT, and 52.5% recommended family screening. AATD is now well described in the literature as a source of hepatic complications, with an increased risk of fibrosis and HCC [<xref rid="apt70183-bib-0003" ref-type="bibr">3</xref>]. The complexity of managing heterozygous patients, often associated with cofactors such as alcoholism or MASH, further obscures the diagnosis. This situation is corroborated by previous studies, such as Cheeney et&#160;al. in 2020, which reported a high prevalence of the Z allele amongst MASH patients, and Abu Rmilah et&#160;al. in 2021, which reported that 9.7% of liver transplant recipients have a Pi&#8208;MZ phenotype [<xref rid="apt70183-bib-0010" ref-type="bibr">10</xref>, <xref rid="apt70183-bib-0016" ref-type="bibr">16</xref>]. Amongst these, 22% had metabolic syndrome, 20% had alcoholic liver disease, and 23% had considered cryptogenic cirrhosis. Recent studies indicate that cirrhosis in Pi&#8208;MZ heterozygous patients progresses more rapidly, with higher MELD scores, more complications, increased need for LT, and higher mortality rates [<xref rid="apt70183-bib-0011" ref-type="bibr">11</xref>, <xref rid="apt70183-bib-0017" ref-type="bibr">17</xref>]. This accelerated deterioration can be attributed to AAT's role of AAT as an acute&#8208;phase protein in inflammation, where its accumulation is exacerbated under stress. Additionally, AAT's immunomodulatory function may contribute to ACLF development [<xref rid="apt70183-bib-0018" ref-type="bibr">18</xref>]. Another diagnostic obstacle is that AATD is often associated with pulmonary disease, which is better known to pulmonologists (61%) than hepatologists (12%), leading practitioners to expect pulmonary symptoms before considering AATD. However, pulmonary symptoms were rare in our cohort (less than 9% had emphysema and were smokers). A 2019 study found increased COPD diagnoses in Pi&#8208;MZ cirrhotic patients compared to those in Pi&#8208;MM patients (15.4% vs. 9%, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) [<xref rid="apt70183-bib-0009" ref-type="bibr">9</xref>]. In our study, 7% of patients had obstructive syndrome, but only 75% had pulmonary function tests, potentially explaining this difference.</p><p>Although heterozygosity has a significant impact on liver disease, it is crucial to differentiate between homozygous and heterozygous patients. In our cohort, amongst the genotyped patients who were homozygous, 100% had been diagnosed before LT and transplanted for AATD, unlike heterozygous patients, diagnosed in 56% of cases post&#8208;LT, primarily transplanted for cirrhosis due to alcohol consumption (44%) or MASH (6%).</p><p>Although intravenous AAT augmentation is an established treatment for AATD&#8208;associated lung disease, its impact on the liver remains controversial [<xref rid="apt70183-bib-0019" ref-type="bibr">19</xref>]. LT is the primary treatment for advanced AATD&#8208;related cirrhosis, with excellent long&#8208;term survival rates (95% at 10&#8201;years in a French paediatric cohort, 70% in an American adult cohort) [<xref rid="apt70183-bib-0020" ref-type="bibr">20</xref>, <xref rid="apt70183-bib-0021" ref-type="bibr">21</xref>]. However, emerging treatments, such as fazirsiran (siRNA), offer promising new avenues for managing liver damage in AATD patients, potentially benefiting even those with minimal liver involvement. Other molecules designed to reduce protein accumulation in hepatocytes are also under study, promising a significant shift in AATD management [<xref rid="apt70183-bib-0022" ref-type="bibr">22</xref>].</p><p>In conclusion, underdiagnosis of AATD in LT candidates significantly impairs patient management. Our study showed that only 40% of AATD patients were diagnosed with pre&#8208;LT, revealing major gaps in current screening practices. Although LT effectively cures patients, earlier diagnosis is not only relevant for implementing preventive lifestyle measures and preventing rapid hepatic deterioration for cirrhotic patients&#8212;but also for family screening. Enhancing AATD awareness and implementing systematic screening protocols are critical. Emerging therapies, such as siRNA, offer promising prospects for the treatment of AATD&#8208;related liver diseases. Improved diagnostic practices and new treatments will substantially enhance patient outcomes and overall management of AATD.</p></sec><sec id="apt70183-sec-0023"><title>Author Contributions</title><p>
<bold>Manon Evain:</bold> conceptualization, investigation, methodology, writing &#8211; original draft, funding acquisition, formal analysis. <bold>Isaac Ruiz:</bold> funding acquisition. <bold>Teresa Antonini:</bold> funding acquisition. <bold>Guillaume Lassailly:</bold> funding acquisition. <bold>Alessandra Mazzola:</bold> funding acquisition. <bold>Pauline Houssel Debry:</bold> funding acquisition. <bold>Laure Elkrief:</bold> funding acquisition. <bold>Rodolphe Anty:</bold> funding acquisition. <bold>Myl&#232;ne Sebagh:</bold> funding acquisition. <bold>Philippe Ichai:</bold> funding acquisition. <bold>Daniel Cherqui:</bold> validation. <bold>Didier Samuel:</bold> validation. <bold>Ilias Kounis:</bold> formal analysis, funding acquisition. <bold>Audrey Coilly:</bold> conceptualization, investigation, writing &#8211; review and editing, validation, methodology, visualization, project administration, software, data curation, supervision, resources.</p></sec><sec sec-type="COI-statement" id="apt70183-sec-0020"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="apt70183-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Data S1.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="APT-62-193-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><sec sec-type="data-availability" id="apt70183-sec-0022"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="apt70183-bibl-0001"><title>References</title><ref id="apt70183-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="apt70183-cit-0001"><string-name name-style="western"><given-names>M.</given-names><surname>Fromme</surname></string-name>, <string-name name-style="western"><given-names>C. V.</given-names><surname>Schneider</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Trautwein</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Brunetti&#8208;Pierri</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Strnad</surname></string-name>, &#8220;<article-title>Alpha&#8208;1 Antitrypsin Deficiency: A Re&#8208;Surfacing Adult Liver Disorder</article-title>,&#8221; <source>Journal of Hepatology</source><volume>76</volume> (<year>2022</year>): <fpage>946</fpage>&#8211;<lpage>958</lpage>.<pub-id pub-id-type="pmid">34848258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2021.11.022</pub-id></mixed-citation></ref><ref id="apt70183-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="apt70183-cit-0002"><string-name name-style="western"><given-names>I.</given-names><surname>Blanco</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Bueno</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Diego</surname></string-name>, et&#160;al., &#8220;<article-title>Alpha&#8208;1 Antitrypsin pi*Z Gene Frequency and pi*ZZ Genotype Numbers Worldwide: An Update</article-title>,&#8221; <source>International Journal of Chronic Obstructive Pulmonary Disease</source><volume>12</volume> (<year>2017</year>): <fpage>561</fpage>&#8211;<lpage>569</lpage>.<pub-id pub-id-type="pmid">28243076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/COPD.S125389</pub-id><pub-id pub-id-type="pmcid">PMC5315200</pub-id></mixed-citation></ref><ref id="apt70183-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="apt70183-cit-0003"><string-name name-style="western"><given-names>M.</given-names><surname>Fromme</surname></string-name>, <string-name name-style="western"><given-names>C. V.</given-names><surname>Schneider</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Pereira</surname></string-name>, et&#160;al., &#8220;<article-title>Hepatobiliary Phenotypes of Adults With Alpha&#8208;1 Antitrypsin Deficiency</article-title>,&#8221; <source>Gut</source><volume>71</volume> (<year>2022</year>): <fpage>415</fpage>&#8211;<lpage>423</lpage>.<pub-id pub-id-type="pmid">33632708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2020-323729</pub-id></mixed-citation></ref><ref id="apt70183-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="apt70183-cit-0004"><string-name name-style="western"><given-names>K.</given-names><surname>Hamesch</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Mandorfer</surname></string-name>, <string-name name-style="western"><given-names>V. M.</given-names><surname>Pereira</surname></string-name>, et&#160;al., &#8220;<article-title>Liver Fibrosis and Metabolic Alterations in Adults With Alpha&#8208;1&#8208;Antitrypsin Deficiency Caused by the pi*ZZ Mutation</article-title>,&#8221; <source>Gastroenterology</source><volume>157</volume> (<year>2019</year>): <fpage>705</fpage>&#8211;<lpage>719</lpage>.<pub-id pub-id-type="pmid">31121167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2019.05.013</pub-id></mixed-citation></ref><ref id="apt70183-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="apt70183-cit-0005"><string-name name-style="western"><given-names>M.</given-names><surname>Ruiz</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Lacaille</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Berthiller</surname></string-name>, et&#160;al., &#8220;<article-title>Liver Disease Related to alpha1&#8208;Antitrypsin Deficiency in French Children: The DEFI&#8208;ALPHA Cohort</article-title>,&#8221; <source>Liver International</source><volume>39</volume> (<year>2019</year>): <fpage>1136</fpage>&#8211;<lpage>1146</lpage>.<pub-id pub-id-type="pmid">30589493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.14035</pub-id></mixed-citation></ref><ref id="apt70183-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="apt70183-cit-0006"><string-name name-style="western"><given-names>P.</given-names><surname>Strnad</surname></string-name>, <string-name name-style="western"><given-names>N. G.</given-names><surname>McElvaney</surname></string-name>, and <string-name name-style="western"><given-names>D. A.</given-names><surname>Lomas</surname></string-name>, &#8220;<article-title>Alpha(1)&#8208;Antitrypsin Deficiency</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>382</volume> (<year>2020</year>): <fpage>1443</fpage>&#8211;<lpage>1455</lpage>.<pub-id pub-id-type="pmid">32268028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra1910234</pub-id></mixed-citation></ref><ref id="apt70183-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="apt70183-cit-0007"><string-name name-style="western"><given-names>L.</given-names><surname>Balcar</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Scheiner</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Urheu</surname></string-name>, et&#160;al., &#8220;<article-title>Alpha&#8208;1 Antitrypsin pi *Z Allele Is an Independent Risk Factor for Liver Transplantation and Death in Patients With Advanced Chronic Liver Disease</article-title>,&#8221; <source>Journal of High Energy Physics Reports</source><volume>4</volume> (<year>2022</year>): <elocation-id>100562</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhepr.2022.100562</pub-id><pub-id pub-id-type="pmcid">PMC9513767</pub-id><pub-id pub-id-type="pmid">36176936</pub-id></mixed-citation></ref><ref id="apt70183-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="apt70183-cit-0008"><string-name name-style="western"><given-names>P.</given-names><surname>Strnad</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Buch</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Hamesch</surname></string-name>, et&#160;al., &#8220;<article-title>Heterozygous Carriage of the alpha1&#8208;Antitrypsin pi*Z Variant Increases the Risk to Develop Liver Cirrhosis</article-title>,&#8221; <source>Gut</source><volume>68</volume> (<year>2019</year>): <fpage>1099</fpage>&#8211;<lpage>1107</lpage>.<pub-id pub-id-type="pmid">30068662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2018-316228</pub-id></mixed-citation></ref><ref id="apt70183-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="apt70183-cit-0009"><string-name name-style="western"><given-names>M.</given-names><surname>Mandorfer</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Bucsics</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Hutya</surname></string-name>, et&#160;al., &#8220;<article-title>Liver Disease in Adults With alpha1&#8208;Antitrypsin Deficiency</article-title>,&#8221; <source>United European Gastroenterology Journal</source><volume>6</volume> (<year>2018</year>): <fpage>710</fpage>&#8211;<lpage>718</lpage>.<pub-id pub-id-type="pmid">30083333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2050640618764057</pub-id><pub-id pub-id-type="pmcid">PMC6068794</pub-id></mixed-citation></ref><ref id="apt70183-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="apt70183-cit-0010"><string-name name-style="western"><given-names>A.</given-names><surname>Abu Rmilah</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Fencl</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Watt</surname></string-name>, et&#160;al., &#8220;<article-title>Association of Alpha 1 Antitrypsin Phenotype and Development of Advanced Liver Disease and Pulmonary Complications Before and After Liver Transplantation</article-title>,&#8221; <source>Transplantation</source><volume>105</volume> (<year>2021</year>): <fpage>1576</fpage>&#8211;<lpage>1584</lpage>.<pub-id pub-id-type="pmid">32732616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/TP.0000000000003390</pub-id></mixed-citation></ref><ref id="apt70183-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="apt70183-cit-0011"><string-name name-style="western"><given-names>V. L.</given-names><surname>Chen</surname></string-name>, <string-name name-style="western"><given-names>D. A.</given-names><surname>Burkholder</surname></string-name>, <string-name name-style="western"><given-names>I. J.</given-names><surname>Moran</surname></string-name>, et&#160;al., &#8220;<article-title>Hepatic Decompensation Is Accelerated in Patients With Cirrhosis and Alpha&#8208;1 Antitrypsin pi *MZ Genotype</article-title>,&#8221; <source>JHEP Reports</source><volume>4</volume> (<year>2022</year>): <elocation-id>100483</elocation-id>.<pub-id pub-id-type="pmid">35571533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhepr.2022.100483</pub-id><pub-id pub-id-type="pmcid">PMC9097455</pub-id></mixed-citation></ref><ref id="apt70183-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="apt70183-cit-0012"><string-name name-style="western"><given-names>L.</given-names><surname>Balcar</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Fromme</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Kappe</surname></string-name>, et&#160;al., &#8220;<article-title>Severe Alpha&#8208;1 Antitrypsin Deficiency Shows a Higher Risk of Complications After First Decompensation Compared to Other Aetiologies of Cirrhosis</article-title>,&#8221; <source>JHEP Reports</source> (<year>2025</year>): <elocation-id>101398</elocation-id>.<pub-id pub-id-type="pmid">40535554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhepr.2025.101398</pub-id><pub-id pub-id-type="pmcid">PMC12174978</pub-id></mixed-citation></ref><ref id="apt70183-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="apt70183-cit-0013"><string-name name-style="western"><given-names>R. S.</given-names><surname>Shah</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Alsuleiman</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Bena</surname></string-name>, <string-name name-style="western"><given-names>J. K.</given-names><surname>Stoller</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Wakim&#8208;Fleming</surname></string-name>, &#8220;<article-title>Alpha&#8208;1 Antitrypsin Deficiency Is Under&#8208;Recognized in Individuals With Cirrhosis Undergoing Liver Transplantation</article-title>,&#8221; <source>European Journal of Gastroenterology &amp; Hepatology</source><volume>33</volume> (<year>2021</year>): <fpage>e233</fpage>&#8211;<lpage>e238</lpage>.<pub-id pub-id-type="pmid">33252420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MEG.0000000000002005</pub-id></mixed-citation></ref><ref id="apt70183-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="apt70183-cit-0014"><string-name name-style="western"><given-names>G.</given-names><surname>Eysenbach</surname></string-name>, &#8220;<article-title>Improving the Quality of Web Surveys: The Checklist for Reporting Results of Internet E&#8208;Surveys (CHERRIES)</article-title>,&#8221; <source>Journal of Medical Internet Research</source><volume>6</volume> (<year>2004</year>): <elocation-id>e34</elocation-id>.<pub-id pub-id-type="pmid">15471760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/jmir.6.3.e34</pub-id><pub-id pub-id-type="pmcid">PMC1550605</pub-id></mixed-citation></ref><ref id="apt70183-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="apt70183-cit-0015"><string-name name-style="western"><given-names>C. V.</given-names><surname>Schneider</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Hamesch</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Gross</surname></string-name>, et&#160;al., &#8220;<article-title>Liver Phenotypes of European Adults Heterozygous or Homozygous for pi *Z Variant of AAT (Pi *MZ vs pi *ZZ Genotype) and Noncarriers</article-title>,&#8221; <source>Gastroenterology</source><volume>159</volume> (<year>2020</year>): <fpage>534</fpage>&#8211;<lpage>548</lpage>.<pub-id pub-id-type="pmid">32376409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2020.04.058</pub-id></mixed-citation></ref><ref id="apt70183-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="apt70183-cit-0016"><string-name name-style="western"><given-names>G.</given-names><surname>Cheeney</surname></string-name>, <string-name name-style="western"><given-names>L. J.</given-names><surname>Pac</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Gopal</surname></string-name>, et&#160;al., &#8220;<article-title>Increased Frequency of Heterozygous Alpha&#8208;1&#8208;Antitrypsin Deficiency in Liver Explants From Nonalcoholic Steatohepatitis Patients</article-title>,&#8221; <source>Liver Transplantation</source><volume>26</volume> (<year>2020</year>): <fpage>17</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">31597010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/lt.25652</pub-id></mixed-citation></ref><ref id="apt70183-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="apt70183-cit-0017"><string-name name-style="western"><given-names>B.</given-names><surname>Schaefer</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Mandorfer</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Viveiros</surname></string-name>, et&#160;al., &#8220;<article-title>Heterozygosity for the Alpha&#8208;1&#8208;Antitrypsin Z Allele in Cirrhosis Is Associated With More Advanced Disease</article-title>,&#8221; <source>Liver Transplantation</source><volume>24</volume> (<year>2018</year>): <fpage>744</fpage>&#8211;<lpage>751</lpage>.<pub-id pub-id-type="pmid">29573137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/lt.25057</pub-id><pub-id pub-id-type="pmcid">PMC6032913</pub-id></mixed-citation></ref><ref id="apt70183-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="apt70183-cit-0018"><string-name name-style="western"><given-names>F.</given-names><surname>Meister</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Lurje</surname></string-name>, <string-name name-style="western"><given-names>U. P.</given-names><surname>Neumann</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Trautwein</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Strnad</surname></string-name>, &#8220;<article-title>Heterozygosity for the Alpha&#8208;1&#8208;Antitrypsin Z Allele in Cirrhosis Is Associated With More Advanced Disease</article-title>,&#8221; <source>Liver Transplantation</source><volume>25</volume> (<year>2019</year>): <fpage>342</fpage>&#8211;<lpage>343</lpage>.<pub-id pub-id-type="pmid">30525305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/lt.25393</pub-id></mixed-citation></ref><ref id="apt70183-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="apt70183-cit-0019"><string-name name-style="western"><given-names>M.</given-names><surname>Fromme</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Hamesch</surname></string-name>, <string-name name-style="western"><given-names>C. V.</given-names><surname>Schneider</surname></string-name>, et&#160;al., &#8220;<article-title>Alpha&#8208;1 Antitrypsin Augmentation and the Liver Phenotype of Adults With Alpha&#8208;1 Antitrypsin Deficiency (Genotype pi *ZZ)</article-title>,&#8221; <source>Clinical Gastroenterology and Hepatology</source><volume>22</volume> (<year>2024</year>): <fpage>283</fpage>&#8211;<lpage>294</lpage>.<pub-id pub-id-type="pmid">37716616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2023.08.038</pub-id></mixed-citation></ref><ref id="apt70183-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="apt70183-cit-0020"><string-name name-style="western"><given-names>E. J.</given-names><surname>Carey</surname></string-name>, <string-name name-style="western"><given-names>V. N.</given-names><surname>Iyer</surname></string-name>, <string-name name-style="western"><given-names>D. R.</given-names><surname>Nelson</surname></string-name>, <string-name name-style="western"><given-names>J. H.</given-names><surname>Nguyen</surname></string-name>, and <string-name name-style="western"><given-names>M. J.</given-names><surname>Krowka</surname></string-name>, &#8220;<article-title>Outcomes for Recipients of Liver Transplantation for Alpha&#8208;1&#8208;Antitrypsin Deficiency&#8208;Related Cirrhosis</article-title>,&#8221; <source>Liver Transplantation</source><volume>19</volume> (<year>2013</year>): <fpage>1370</fpage>&#8211;<lpage>1376</lpage>.<pub-id pub-id-type="pmid">24019185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/lt.23744</pub-id></mixed-citation></ref><ref id="apt70183-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="apt70183-cit-0021"><string-name name-style="western"><given-names>O.</given-names><surname>Guillaud</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Jacquemin</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Couchonnal</surname></string-name>, et&#160;al., &#8220;<article-title>Long Term Results of Liver Transplantation for Alpha&#8208;1 Antitrypsin Deficiency</article-title>,&#8221; <source>Digestive and Liver Disease</source><volume>53</volume> (<year>2021</year>): <fpage>606</fpage>&#8211;<lpage>611</lpage>.<pub-id pub-id-type="pmid">33139195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dld.2020.10.016</pub-id></mixed-citation></ref><ref id="apt70183-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="apt70183-cit-0022"><string-name name-style="western"><given-names>K.</given-names><surname>Remih</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Amzou</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Strnad</surname></string-name>, &#8220;<article-title>Alpha1&#8208;Antitrypsin Deficiency: New Therapies on the Horizon</article-title>,&#8221; <source>Current Opinion in Pharmacology</source><volume>59</volume> (<year>2021</year>): <fpage>149</fpage>&#8211;<lpage>156</lpage>.<pub-id pub-id-type="pmid">34256305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coph.2021.06.001</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>